ONCOmmunity

ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).

By: Sarah C Markt, Irene M Shui, Robert H Unger, Yuksel Urun, Christine D Berg, Amanda Black, Paul Brennan, H Bas Bueno-de-Mesquita, Susan M Gapstur, Edward Giovannucci, Christopher Haiman, Brian Henderson, Robert N Hoover, David J Hunter, Timothy J Key, Kay-Tee Khaw, Federico Canzian, Nerea Larranga, Loic Le Marchand, Jing Ma, Alessio Naccarati, Afshan Siddiq, Meir J Stampfer, Par Stattin, Victoria L Stevens, Daniel O Stram, Anne Tjønneland, Ruth C Travis, Dimitrios Trichopoulos, Regina G Ziegler, Sara Lindstrom, Peter Kraft, Lorelei A Mucci, Toni K Choueiri, Kathryn M Wilson

Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
2015-4-3; doi: 10.1002/pros.23035

Abstract

Background

ABO blood group has been associated with risk of cancers of the pancreas, stomach, ovary, kidney, and skin, but has not been evaluated in relation to risk of aggressive prostate cancer.

Methods

We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). Unconditional logistic regression was used to calculate age and study-adjusted odds ratios and 95% confidence intervals for the association between blood type, genotype, and risk of aggressive prostate cancer (Gleason score ≥8 or locally advanced/metastatic disease (stage T3/T4/N1/M1).

Results

We found no association between ABO blood type and risk of aggressive prostate cancer (Type A: OR = 0.97, 95%CI = 0.87-1.08; Type B: OR = 0.92, 95%CI =n0.77-1.09; Type AB: OR = 1.25, 95%CI = 0.98-1.59, compared to Type O, respectively). Similarly, there was no association between "dose" of A or B alleles and aggressive prostate cancer risk.

Conclusions